Trial Profile
Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Adverse reactions; Registrational
- Sponsors Rhythm
- 09 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Jun 2023 Results (n=13) assessing changes in age-appropriate weight-related parameters after 6 months of treatment with setmelanotide in patients with HO presented at the 105th Annual Meeting of the Endocrine Society
- 03 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.